Mechanistic Insights Into Durable Pulmonary Vein Isolation Achieved By Second-Generation Cryoballoon Ablation

Yasuo Okumura, Ichiro Watanabe, Kazuki Iso, Keiko Takahashi, Koichi Nagashima, Kazumasa Sonoda, Hiroaki Mano, Naoko Yamaguchi, Rikitake Kogawa, Ryuta Watanabe, Masaru Arai, Kimie Ohkubo, Sayaka Kurokawa, Toshiko Nakai, Atsushi Hirayama

Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Abstract

Background: The mechanism explaining the efficacy of cryoballoon ablation (CBA) for atrial fibrillation has not been clarified.

Methods and Results: We compared lesion characteristics between patients in whom pulmonary vein isolation (PVI) was performed by CBA (n=56) and those by contact force (CF)-based RF ablation (n=56). We evaluated the 3-dimensional PV morphology before and after cryoballoon inflation. After PVI, a 3D left atrial voltage map was created. Pacing (10 mA and 2 ms) was performed within the low voltage area from the original PV ostial surface by 5.2±3.3 mm, but at sites with (vs. sites without) residual PV potential/dormant conduction, the extent of the PV distension was reduced (2.6±3.4 mm vs. 5.3±3.3 mm, P<0.0001). The unexcitable ablated tissue around the PVs was significantly wider in CB patients than in CF patients (16.7±5.1 mm vs. 5.3±2.3 mm, P<0.0001).

Conclusions: Use of the cryoballoon significantly distends the PV. Without this extensive distention, PVI may not be successful. CBA seems to yield wide unexcitable ablation zones. These factors seem to explain the durability of CBA lesions.

Introduction

Cryothermal energy has emerged as an alternative ablation energy that does not issue in the clot formation and excessive tissue damage that occur with radiofrequency (RF) energy-based catheter ablation. Although cryothermal energy is a milder and safer form of energy than RF energy, pulmonary vein isolation (PVI) performed with a second-generation cryoballoon has been highly successful in cases of paroxysmal atrial fibrillation (AF) and comparable to PVI performed by point by point-based RF ablation or even contact force (CF)-based RF ablation. Despite the efficacy of cryoballoon ablation (CBA), however, some patients suffer recurrence of the AF, due mainly to PV reconnections or to non-PV triggers. Thus far, the mechanisms explaining durable and non-durable lesion formation around the PV ostium by means of second-generation CBA have not been fully investigated. Because establishing good balloon surface-to-tissue contact is essential for successful CBA of AF, we investigated, by means of 3-dimensional (3D) geometric imaging, how the inflated balloon surface contacts the 4 PVs. We then characterized lesions created around the PV ostia by CBA and those created by CF-based ablation to clarify the mechanism responsible for the efficacy of CBA.

Material and Methods

Study Patients

The study involved 112 consecutive patients treated for AF (symptomatic paroxysmal AF [n=88] or persistent AF [n=24]) at Nihon University Itabashi Hospital between September 2014 and December 2015. The patient series comprised 72 men and 40 women with a mean±SD age of 63.8±7.7 years and median duration of AF of 18 months (interquartile range, 6–48 months). Patients were blindly (but not randomly) assigned to 1 of 2 ablation procedures: PVI performed by means of second-generation CBA (CBA group, n=56) and PVI performed by means of CF-based RF catheter ablation (CF group, n=56). Written informed consent was obtained from all patients. All antiarrhythmic drugs were withdrawn for at least 5 half-lives prior to the procedure. Transesophageal and transthoracic echocardiography were performed 1 day before the ablation procedure with an ACUSON Sequoia C256 echocardiography system (Siemens Medical Solutions USA, Inc., Malvern, PA). LA diameter (LAD) and maximum LA volume (by the prolate ellipsoid method) were determined, and the left ventricular ejection fraction (LVEF) was determined by means of M-mode echocardiography (Teichholz method). Multi-slice computed tomography was performed with a 320-detector row, dynamic volume scanner (Aquilion ONE; Toshiba Medical Systems, Tokyo, Japan) in all patients for 3D reconstruction of the left atrium (LA) and PVs before ablation.

Electrophysiologic Study and Ablation

Electrophysiologic study was performed in all patients under conscious sedation achieved with dexmedetomidine and fentanyl.
After vascular access was obtained, single transseptal puncture was performed, and intravenous heparin was administered to maintain an activated clotting time of >300 seconds.\textsuperscript{[11][12]}

**CBA**

In all patients who underwent CBA, 2 SL0 long sheaths (St. Jude Medical, Inc., St. Paul, MN, USA) were inserted into the LA via the puncture hole.\textsuperscript{[11]} The 3D geometry of the LA and PVs was reconstructed with an EnSite NavX mapping system (St. Jude Medical) from data obtained with a 20-pole circular mapping catheter (4-mm interelectrode spacing; Inquiry AFocus II EB catheter; St. Jude Medical) or a 10-pole mapping catheter with 5-mm interelectrode spacing (Snake, Japan Lifeline, Inc., Tokyo, Japan) through 1 of the 2 SL0 sheaths. An exchange length (0.035 inch) guidewire was introduced into the left superior (LS) PV, over which another SL0 sheath was exchanged for a 15Fr deflectable sheath (Flexcath, Medtronic, Inc., Minneapolis, MN, USA). An Artic Front Advance 28-mm cryoballoon (CB-Adv) (Medtronic) with an Achieve inner lumen mapping catheter was placed in the LA through the steerable 15Fr sheath. The CB-Adv was then inflated and advanced successively to each PV ostium to establish optimal PV occlusion, determined by the absence of contrast leakage. To avoid a vigorous wedging of the balloon inside the PVs, we used the — proximal-seal\textsuperscript{[1]} technique for all RSPV and LSPV, i.e., withdrawing the inflated cryoballoon until a small leak was observed and then performing a small repositioning of the cryoballoon were applied.\textsuperscript{[13]} Cryoenergy was delivered to each PV after occlusion was established. Ablation of each PV antrum was performed with a 180-s application followed by a 120-s or 180-s application. Continuous monitoring of the phrenic nerve during ablation of the right superior and inferior PVs (RSPV and RIPV, respectively) was systematically performed by pacing the right phrenic nerve from the superior vena cava.\textsuperscript{[11]} After each CBA procedure, PVI was confirmed with the Lasso catheters. If residual PV potentials were revealed, additional cryoenergy was delivered.

**CF-Based RF Ablation**

In all patients who underwent CF-based ablation, extensive encircling ipsilateral PVI was performed, guided by a double Lasso catheter and the 3D geometric map reconstructed with the CARTO mapping system (Biosense Webster, Inc., Diamond Bar, CA), as previously reported.\textsuperscript{[12]} The point-by-point ablation method was used by a CF-sensing irrigated tip catheter with 2-5-2 mm spacing (Thermocool Smart Touch; Biosense Webster) under VisiTag system guidance.\textsuperscript{[12]} RF energy was delivered at a maximum power output of 25–30 W and a target CF of 10–20 grams with a force-time integral of > 400 gs. The upper temperature limit was set to 43°C at a saline irrigation rate of 17–30 mL/min (CoolFlow Pump; Biosense Webster). PVI was confirmed with the Lasso catheters. If the PV remained connected, additional touch-up CF-guided ablation lesions were created until PVI was achieved.

**Creation of 3D Images of the PV Ostium After Inflation of the Cryoballoon**

For 21 of the 56 patients who underwent CBA, we created 3D images of the distended PV ostium after inflating the cryoballoon. Upon completion of the CBA procedure, the Snake mapping catheter was advanced into the LA through the SL0 sheath. The balloon was again inflated, and we created the 3D geometry of the distended PV by carefully manipulating the mapping catheter around the inflated balloon surface, which was now in contact with the endocardium at the target PV ostium [Figure 1]. To minimize distortion by the mapping catheter, we created the 3D geometric image of the expanded PV surface during pullback of the mapping catheter, which we performed in a step-by-step manner from different directions.\textsuperscript{[14]} At each PV, we measured the amount of balloon-induced distention at the PV ostium by measuring the distance between the original PV surface and the surface of the distended PV at the 8 segments: the superior, antero-superior, anterior, antero-inferior, inferior, postero-inferior, posterior, and postero-superior segments [Figure 1]. Finally, we excluded the diameter (2mm) of the tip of the mapping catheter from the distance between the original PV surface and surface of the distended PV, and used that distance for the analysis, because...
the catheter tip further distended the ostia beyond that of the CB by 2mm.

Identification and Measurement of Low Voltage Areas and Unexcitable Scar Tissue

For each patient, after complete CF-based PVI or completion of 2 (or 3) cryoenergy applications at each PV, a 3D LA voltage map was created, and the percentage of the low voltage area (<0.5 mV), i.e., the ratio of the low voltage area to the total PV-LA surface area (defined by the surface area of the total LA and the distal segments of the PVs 10 mm from each PV ostium) was calculated. After placement of the circular mapping catheter distally within the PV, pacing (10 mA, 2 ms) was performed by the ablation catheter (or the mapping catheter) with 2-mm interelectrode spacing within the low voltage area from the ablation line to the distal segments of the PVs, and we identified whether pacing captured the distal PV tissues or not by the circular mapping catheter. Electrically unexcitable regions were defined as sites where there was no pace capture [Figure 2]. We measured the distance from the edge of the low voltage area to the center of the tag at the unexcitable region in each of the PV segments (except the inferior segment) shown in [Figure 2]. We did not include the RIPV or left inferior (LI) PV because of the difficulty in identifying sites of capture within the short sleeve of each of these PVs.

Ensuring Complete PVI

In patients who underwent CBA, if residual PV potentials around the PV antrum were identified on the 3D LA voltage maps and Lasso catheter recordings despite a total of 3 cryoenergy applications, touch-up RF ablation was performed at acute PV conduction sites with a 4-mm irrigated tip Safire BLU Duo ablation catheter with 2-5-2 mm spacing (St. Jude Medical).

In all patients, 30 minutes after PVI, adenosine triphosphate (ATP) (30 mg) was administered intravenously by bolus injection to provoke dormant PV conduction. Sites of dormant PV conduction were verified with the circular mapping catheter. Sites of residual PV potential and/or breakthrough sites, i.e., sites of dormant PV conduction, were categorized according to the PV segment in which they were revealed. RF energy was applied to the conduction gaps until the dormant PV conduction disappeared. Cavo-tricuspid isthmus ablation was performed when typical atrial flutter was induced by burst atrial pacing or observed clinically.

Post-Ablation Follow-Up

All patients’ antiarrhythmic drugs were resumed after the procedure but then stopped after a 3-month post-ablation blanking period. All underwent routine follow-up examinations at our outpatient clinic 2 weeks after ablation, 1 month after ablation, and at 1-to-3-month intervals thereafter for at least 6 months. Twenty-four-hour Holter monitoring was scheduled between 3 and 6 months after ablation. An ECG event recorder was used if a patient reported cardiac symptoms. All documented AF episodes of >30-s duration on the standard ECG, ECG event monitor, or 24-hour Holter recording were considered a recurrence.

Statistical Analysis

Continuous variables are expressed as mean±SD or median and interquartile ranges. Differences in continuous variables between the CBA group and CF group were analyzed by unpaired t-test or Mann-Whitney U-test, as appropriate. Differences in the extent of distention between the 4 PVs and between PV segments were examined by analysis of variance (ANOVA). Differences in categorical variables were analyzed by chi-square test. P <0.05 was accepted as statistically significant. All statistical analyses were performed with JMP 10 software (SAS Institute, Cary, NC).

Results

Patient and Procedural Characteristics

Patient characteristics and transthoracic echocardiographic variables are summarized per group in [Table 1]. There was no significant difference in clinical characteristics, LAD, or LVEF between the CBA group and the CF group.

Residual PV Potentials After CBA and Dormant PV Conduction Provoked by ATP

A total of 2.2±0.8 cryoenergy applications (for a total freezing time of 328±98 s for each PV) successfully isolated 198 of the total 224 (88%) PVs. The average nadir balloon temperatures were -50.3±6.2 degrees for the RSPV, -49.2±4.9 degree for the LSPV, -44.4± -6.0 degrees for the RIPV, and -47.9±5.9 degrees for the LIPV. The average total cryoenergy application times were 37.6±11.9 s for the RSPV, 33.2±9.9 s for the LSPV, 36.8±13.3 s for the RIPV, and 37.5±12.5 s for the LIPV. The mean balloon size used was 19.5±2.1 mm.

Table 1: Clinical Characteristics of Patients Per Study Group

<table>
<thead>
<tr>
<th></th>
<th>CBA group (n=56)</th>
<th>CF group (n=56)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.3±9.8</td>
<td>63.3±10.9</td>
<td>.6371</td>
</tr>
<tr>
<td>Sex ratio (M/F)</td>
<td>35/21</td>
<td>37/19</td>
<td>.6933</td>
</tr>
<tr>
<td>Duration of AF (months)</td>
<td>12 (5–36)</td>
<td>24 (6–60)</td>
<td>.3494</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.8±4.1</td>
<td>24.3±4.3</td>
<td>.4646</td>
</tr>
<tr>
<td>AF type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxysmal/Persistent</td>
<td>46/10</td>
<td>42/14</td>
<td>.3570</td>
</tr>
<tr>
<td>Hypertension</td>
<td>26 (46)</td>
<td>29 (52)</td>
<td>.5706</td>
</tr>
<tr>
<td>Heart failure</td>
<td>6 (11)</td>
<td>3 (5)</td>
<td>.4898</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12 (21)</td>
<td>6 (11)</td>
<td>.1975</td>
</tr>
<tr>
<td>Echocardiographic measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left atrial diameter (mm)</td>
<td>39.2±6.6</td>
<td>39.7±5.4</td>
<td>.6752</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>67.7±9.5</td>
<td>67.4±8.1</td>
<td>.9018</td>
</tr>
<tr>
<td>Left atrial volume (mL)</td>
<td>40.4±17.2</td>
<td>46.5±18.9</td>
<td>.0744</td>
</tr>
<tr>
<td>CFA ablation</td>
<td>23 (41)</td>
<td>20 (36)</td>
<td>.5600</td>
</tr>
</tbody>
</table>

Values are shown as mean±SD, median and interquartile ranges or n (%) unless otherwise indicated. CBA cryoballoon ablation; CF contact force-based radiofrequency ablation; AF atrial fibrillation; LVEF left ventricular ejection fraction; CFA cavitricuspid isthmus. *per Student t-test, Mann-Whitney U-test, chi-square test, or Fisher’s exact test, as appropriate.
inflated balloon stretched the PV ostium surface by 5.2±3.3 mm. and after cryoballoon inflation are shown in [Figure 4]. Overall, the CBA group. Representative 3D images of the PV and LA before and after PVI, ATP (30 mg) provoked dormant PV conduction in 36.3±13.4 mL, P=0.0063) and lower LVEF (63.3±8.7 vs. 69.7±9.3 %, P=0.0166), were more likely to have persistent AF (39% [7/18] vs. 5 LSPV were without capture) in 19 CF group patients. The low voltage area on the 3D LA map was significantly greater in the CBA group patients than in the CF group patients (44.5±15.2% vs. 36.3±5.4%,respectively, P=0.0350), and unexcitable tissue along the ablation line around the PVs was significantly wider in the CBA group patients than in the CF group patients (16.7±5.1 mm by ANOVA). Complete isolation of all 4 PVs was achieved upon the initial attempt in 38 (68%) of the 56 patients in this group. In the remaining 26 (12%) PVs in 18 (32%) patients, the 3D voltage map and circular mapping catheter recording revealed residual potentials in 28 PV segments (median, 2 [1–2] sites per patient), and these required touch-up ablation to achieve complete PVI. Distribution of the PV segments with a residual potential is shown in [Figure 3]. Fifteen (54%) of the 28 sites with a residual PV potential were located in the inferior region of the RIPV or LIPV. In comparison to patients without residual PV potentials, patients with residual PV potentials were younger (59.1±11.5 vs. 66.7±8.0 years, P=0.0053), had a higher body mass index (25.6±4.9 vs. 22.9±3.3 kg/m2, P=0.0166), were more likely to have persistent AF (39% [7/18] vs. 8% [3/38], P=0.0085), and had a greater LA volume (49.1±20.3 vs. 36.3±13.4 mL, P=0.0063) and lower LVEF (63.3±8.7 vs. 69.7±9.3 %, P=0.0175). In contrast, in the CF group, PVI was achieved for all 224 PVs, i.e., for all 56 patients.

After PVI, ATP (30 mg) provoked dormant PV conduction in 9 (4%) of the 224 PVs (in 9 [16%] of the 56 patients) in the CBA group and in 13 (6%) of the 224 PVs (in 8 [14%] of the 56 patients) in the CF group (P=0.3935). The sites of dormant conduction are shown in [Figure 3]. The sites of dormant conduction showed no regional predilection in the CBA group, but in the CF group, sites of dormant conduction were located mainly in the carina regions of the right and left PVs (amounting to 9/14 [64%] PV segments with dormant conduction).

Cryoballoon-Produced PV Distention
As noted above, a PV distention map was created for 21 patients in the CBA group. Representative 3D images of the PV and LA before and after cryoballoon inflation are shown in [Figure 4]. Overall, the inflated balloon stretched the PV ostium surface by 5.2±3.3 mm.

Regionally, the inflated balloon distended the RSPV, LSPV, and RIPV ostia mainly in the postero-superior direction (as defined by the 3 segments showing the greatest distention), but it distended the LIPV ostium in the superior direction. Distention was significantly less in the opposite segments, i.e., in the anterior, antero-inferior, and inferior segments of the RSPV (4.3±3.1 mm vs. 6.5±3.5 mm in the posterior, postero-superior, and superior segments, P=0.0003), LSPV (4.1±2.8 mm vs. 7.3±3.3 mm, P<0.0001), and RIPV (3.0±2.8 mm vs. 6.3±3.0 mm, P<0.0001), and the antero-inferior, inferior, and postero-inferior segments of the LIPV (2.7±2.4 mm vs. 7.4±2.6 mm for the antero-superior, superior, and postero-superior segments, P<0.0001) [Figure 5]. The residual PV potential/dormant PV conduction was found in 25 (3.7%) of the 672 PV segments (21 patients×4PVs×8 PV segments) in the 20 PVs (24% of the 84 PVs), which was strongly associated with contrast leakage before CBA (18 [90%] PVs vs. 5 [8%] in the 64 PVs without it, P<0.0001). The number of residual PV potential/dormant PV conduction sites differed between segments and increased in the following order: 1 (0.6% of the 168 PV segments [21 patients×8 PV segments]), 5 (3.0%), 7 (4.2%), and 12 (7.2%) segments in the LSPV, RSPV, LIPV, and RIPV, respectively (P=0.0084). Importantly, the extent of PV distension was decreased in the PV segments showing residual PV residual PV potential/ dormant PV conduction (2.6±3.4 mm vs. 5.3±3.3 mm, P<0.0001).

Low Voltage and Unexcitable Scar Areas
Representative examples of the PV ablation lesions and ablation points linked to unexcitable tissue are shown in [Figure 2]. We examined 17 RSPVs and 15 LSPVs (2 LSPVs were without pace capture) in 17 CBA group patients and 19 RSPVs and 14 LSPVs (5 LSPVs were without capture) in 19 CF group patients. The low voltage area on the 3D LA map was significantly greater in the CBA group patients than in the CF group patients (44.5±15.2% vs. 36.3±5.4%,respectively, P=0.0350), and unexcitable tissue along the ablation line around the PVs was significantly wider in the CBA group patients than in the CF group patients (16.7±5.1 mm vs. 11.3±5.2 mm, P=0.0035). The extent of PV distension after cryoballoon inflation and its relation to residual PV potential/dormant conduction in the various segments of the RSPV, RIPV, LSPV, and LIPV. Black lines indicate the extent of PV distention in the various PV segments, and gray lines indicate the mean diameter of original PV ostium. The PV distention was greatest at 3 of the 8 PV segments, and the measurements are shown in black; the remaining measures of PV distention are shown in gray. Open arrows indicate the main direction of PV distention. Abbreviations are as shown in [Figure 3].
Transient phrenic nerve palsy occurred during RSPV ablation in 3 patients (5%) in the CBA group. No other complication was observed in either group. The AF recurrence rate at a median of 12 months was equivalent at 11% (6/56 patients) in the CBA group and 18% (10/56 patients) in the CF group (P=0.4187).

**Discussion**

Results of our investigation into the mechanism explaining the success of CBA in treating AF can be summarized as follows: First, the incidence of ATP-provoked PV dormant conduction after CBA was as low as that after CF-based RF ablation, although touch-up ablation was necessary in 32% of patients who underwent CBA. Second, the inflated balloon stretched the PV ostium by 5.2±3.3 mm, but there were regional differences in the PV distension between the LSPV, RSPV, LIPV, and RIPV. Third, the sites of residual potential or dormant conduction were located in PV segments in which distention resulting from inflation of the cryoballoon was moderate rather than extensive. Fourth, the low voltage area resulting from CBA was significantly greater and the unexcitable tissue along the ablation line was significantly wider than those resulting from CF-based RF ablation.

**Residual PV Potentials after CBA and Dormant PV Conduction After CBA vs. CF-Based RF Ablation**

Previous studies have shown that the efficacy of CBA for paroxysmal AF is similar to that of point-by-point RF ablation, but in some patients undergoing CBA, touch-up ablation is required for complete PVI. In our study, touch-up ablation for residual PV potentials was required to complete the PVI in 26 (12%) of the 224 PVs in 18 (32%) of the 56 patients. Touch-up ablation after CBA has been reported for 0–17% of PVs.\[^{25}\] In our study, patients with residual PV potentials were relatively young, had a relatively high body mass index and large LA volume, and were likely to have persistent AF. In addition, we meticulously identified residual PV potentials using 3D voltage map, and we looked for PV potentials not only inside the PV but also in the PV antrum. These patient characteristics and our procedure might account, at least in part, for the incidence of touch-up ablations in our patient series.

The incidence of dormant PV conduction provoked by ATP in our CBA group was lower but statistically comparable to that in our CF group (4% vs. 6% of PVs). The low incidence of dormant PV conduction we encountered after CBA is well in line with previously reported incidences of 2%–8%.\[^{17}\]–\[^{19}\] Dormant conduction in our point-by-point RF group was relatively low because we used not only CF but also the VisiTag module, which includes catheter stability information. We reported previously that use of this module reduced the commonly reported incidence of dormant conduction.\[^{12}\]–\[^{20}\],\[^{21}\]

**Characteristics of Lesions Created by CBA**

This study clarified the mechanism explaining good lesions achieved with CBA. Although lesion durability has been documented, a detailed explanation has not been provided.\[^{23}\]–\[^{26}\] Adequate CBA occlusion with good balloon-tissue surface contact is important for successful PVI. In theory, extensive, concentric PV distention achieved with the cryoballoon should result in good balloon-tissue surface contact, and we believe that the extensive distention (approximately 7 mm) observed in our study patients was responsible for the creation of ideal ablation lesions around the PV. Nonetheless, our data showed that regional heterogeneity was noted in each PV. The inflated balloon stretched the PV surface in the postero-superior direction in the RSPV, LSPV, RIPV and in the superior direction in the LIPV, resulting in lesser PV distention on the opposite sides. The lesser PV distention was significantly associated with an increased number of residual PV potentials/dormant PV conduction sites.

Similarly, sites requiring touch-up ablation and sites of dormant conduction after CBA are often found in the inferior PVs, especially in the inferior segments of the RIPV.\[^{15}\]–\[^{19}\] In the chronic phase, these sites have been reported to be the common sites of PV reconnection.\[^{9}\]–\[^{10}\],\[^{28}\] Recently published studies\[^{17}\]–\[^{19}\] have suggested that this may be due to malalignment of the cryoballoon, and thus poor balloon-tissue surface contact, in relation to the PV ostium. Therefore, even if PV occlusion by cryoballoon and acute PVI succeed, the lesser PV distention sites can potentially lead to future PV reconnections.

We found that the low voltage area after CBA was significantly larger than that after CF-based RF ablation. Recent studies of CBA have also documented wide and antral ablation lesions.\[^{10}\],\[^{22}\]–\[^{24}\] Nevertheless, the authors assessed only the border line between the ablated and non-ablated regions, and therefore, actual ablated regions within the PV have not been known. We identified the actual ablated regions where PV sleeve tissues were not captured by pacing within the low voltage areas. Unexcitable ablation tissue in the RSPV and LSPV was nearly 3 times longer (16.7 mm) than that (5 mm) achieved by CF-based RF ablation. In fact, the widths of unexcitable ablated tissues that we measured match the reported widths derived from pathological assessment (14±7 mm).\[^{25}\] Interestingly, PV segments with the widest unexcitable scars were well matched with PV segments showing the greatest PV distention (i.e., the superior, postero-superior, and posterior segments) [Figure 5] and [Figure 6], suggesting that extensive PV distention with good balloon-tissue contact results in wider lesions. These ablated lesion characteristics may explain why CBA-based PVI that persists in
the chronic phase was reported in approximately 70% of previously isolated PVs regardless of whether the arrhythmia recurred,[9][10][26] and this percentage is significantly higher than the recently published percentage yield of RF ablation.[26][28]

Clinical Outcomes

Clinical AF recurrence at a median follow up of 12 months was detected in only 6 (11%) of the 56 patients in our CBA group but in 10 (18%) of the 56 patients in our CF group. Recent studies comparing CF-guided RF ablation with CBA have shown statistical equivalence between the 2 technologies.[9][10] CBA produces wider lesions which however are not more effective than the more narrow lesions produced by CF-guided RF ablation. This may relate to the fact that even focused lesions may eliminate triggers and that transmural continuous lesions around the PVs may not be necessary in all cases.[9][10][26]

Limitations

Our study was limited by the size of the patient groups, considering the fact we performed distension assessments in approximately half of the study patients, because of the tedious and time-consuming nature of the assessment. Nonetheless, the subsequent acute and chronic outcome after CBA are similar to other reports, suggesting that our results will be applicable to analysis of CBA performed for other conditions. Measurement of PV distension after cryoballoon inflation may include an artefact since the measurement of distension was not performed using an absolute geometrical/spatial reference. We did not analyze CBA lesions and PV reconnection sites in the chronic phase. Although some differences can be expected in the chronic phase, the trends should be similar to those in the acute phase.[10][26]

Conclusions

PV distension produced by cryoballoon inflation appears to be greater in the postero-superior direction than in the antero-inferior direction. Unsuccessful PVI appears to occur when PV distention is relatively inextensive. Overall, CBA lesions appear to be more durable at the posterior and superior aspects of the PV ostia than at the floor of the RIPV. CBA results in wider ablation lesions and unexcitable ablation zones than those resulting from CF-guided RF ablation. This may explain the high efficacy of CBA for paroxysmal AF.

Conflict Of Interests

None.

Disclosures

None.

References


